血管活性肠肽在体外和体内均可抑制人小细胞肺癌的增殖。
Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.
作者信息
Maruno K, Absood A, Said S I
机构信息
Department of Medicine, Northport Veterans Affairs Medical Center Stony Brook, NY 11768-2290, USA.
出版信息
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14373-8. doi: 10.1073/pnas.95.24.14373.
Abstract
Small-cell lung carcinoma (SCLC) is an aggressive, rapidly growing and metastasizing, and highly fatal neoplasm. We report that vasoactive intestinal peptide inhibits the proliferation of SCLC cells in culture and dramatically suppresses the growth of SCLC tumor-cell implants in athymic nude mice. In both cases, the inhibition was mediated apparently by a cAMP-dependent mechanism, because the inhibition was enhanced by the adenylate cyclase activator forskolin and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in proportion to increases in intracellular cAMP levels, and the inhibition was abolished by selective inhibition of cAMP-dependent protein kinase. If confirmed in clinical trials, this antiproliferative action of vasoactive intestinal peptide may offer a new and promising means of suppressing SCLC in human subjects, without the toxic side effects of chemotherapeutic agents.
摘要
小细胞肺癌（SCLC）是一种侵袭性强、生长迅速且易转移、致死率高的肿瘤。我们报告称，血管活性肠肽可抑制培养的小细胞肺癌细胞的增殖，并显著抑制无胸腺裸鼠体内小细胞肺癌肿瘤细胞植入物的生长。在这两种情况下，这种抑制作用显然是由一种依赖环磷酸腺苷（cAMP）的机制介导的，因为腺苷酸环化酶激活剂福斯高林和磷酸二酯酶抑制剂3 - 异丁基 - 1 - 甲基黄嘌呤可根据细胞内cAMP水平的升高按比例增强这种抑制作用，而通过选择性抑制依赖cAMP的蛋白激酶可消除这种抑制作用。如果在临床试验中得到证实，血管活性肠肽的这种抗增殖作用可能为抑制人类小细胞肺癌提供一种新的、有前景的方法，且无化疗药物的毒副作用。
相似文献
1
Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14373-8. doi: 10.1073/pnas.95.24.14373.
2
Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
Neuroendocrinology. 2002 Nov;76(5):325-38. doi: 10.1159/000066627.
3
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides. 2001 Jun;22(6):879-86. doi: 10.1016/s0196-9781(01)00413-2.
4
Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
Endocrinology. 1997 May;138(5):1930-4. doi: 10.1210/endo.138.5.5116.
5
VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.
Am J Physiol. 1995 Jun;268(6 Pt 1):L1047-51. doi: 10.1152/ajplung.1995.268.6.L1047.
6
Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes.
Biochem J. 1996 May 15;316 ( Pt 1)(Pt 1):87-91. doi: 10.1042/bj3160087.
7
Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
Lung Cancer. 2001 Feb-Mar;31(2-3):203-12. doi: 10.1016/s0169-5002(00)00168-9.
8
Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody.
Life Sci. 1993;52(24):PL267-71. doi: 10.1016/0024-3205(93)90640-o.
9
10
Histamine and the cAMP pathway in the guinea-pig pancreas.
Cell Signal. 1995 Jan;7(1):57-60. doi: 10.1016/0898-6568(94)00058-j.
引用本文的文献
1
Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.
Int J Biol Sci. 2022 Jul 4;18(11):4341-4356. doi: 10.7150/ijbs.71134. eCollection 2022.
2
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.
Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016.
3
Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.
J Cancer Res Clin Oncol. 2014 Oct;140(10):1641-9. doi: 10.1007/s00432-014-1716-1. Epub 2014 Jun 1.
4
VIP inhibits human HepG2 cell proliferation in vitro.
Regul Pept. 2008 Feb 7;146(1-3):285-92. doi: 10.1016/j.regpep.2007.11.002. Epub 2007 Nov 21.
5
Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3435-40. doi: 10.1073/pnas.0410006102. Epub 2005 Feb 22.
6
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9512-7. doi: 10.1073/pnas.1533185100. Epub 2003 Jul 16.
7
Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
Am J Pathol. 2002 Dec;161(6):2241-53. doi: 10.1016/S0002-9440(10)64500-2.
8
Expression and fine mapping of murine vasoactive intestinal peptide receptor 1.
J Mol Neurosci. 2001 Dec;17(3):311-24. doi: 10.1385/JMN:17:3:311.
9
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10555-60. doi: 10.1073/pnas.180313097.
10
Antitumorigenic actions of growth hormone-releasing hormone antagonists.
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):532-4. doi: 10.1073/pnas.97.2.532.
本文引用的文献
1
Protein measurement with the Folin phenol reagent.
J Biol Chem. 1951 Nov;193(1):265-75.
2
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794-9. doi: 10.1073/pnas.95.4.1794.
3
A femtomolar-acting neuroprotective peptide.
J Clin Invest. 1996 May 15;97(10):2299-307. doi: 10.1172/JCI118672.
4
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4345-9. doi: 10.1073/pnas.90.10.4345.
5
Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody.
Life Sci. 1993;52(24):PL267-71. doi: 10.1016/0024-3205(93)90640-o.
6
Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Peptides. 1993 Mar-Apr;14(2):241-6. doi: 10.1016/0196-9781(93)90036-g.
7
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
N Engl J Med. 1994 Oct 27;331(17):1116-21. doi: 10.1056/NEJM199410273311703.
8
Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene.
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2939-43. doi: 10.1073/pnas.92.7.2939.
9
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo.
Eur J Cancer. 1993;29A(10):1450-3. doi: 10.1016/0959-8049(93)90019-c.
10
Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture.
Cancer Res. 1982 Jun;42(6):2159-64.
Zotero 插件